WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Macquarie: Reiterate WuXi Biologics (2269 HK) "Outperform" rating target price of HK$122 https://m.jrj.com.cn/madapter/hk/2021/06/18160332954824.shtml According to a research report published by Macquarie, the CEO of WuXi Biologics (2269 HK) announced that it will raise its guidance for full-year sales and profit growth from 50% to 65%, which is higher than the bank’s expected 57%. It is expected to be in the industry. With rapid growth, the company will continue to perform strongly in the next few years, with a compound annual growth rate of 38% to 50%. The bank pointed out that there are currently 9 vaccine projects under development or production, providing good support for growth. The management’s goal is to increase the number of projects under development to 80 in the future. Macquarie expects that 4 to 5 of the 32 phase III clinical phase products in hand will be core projects, and the peak sales of each can reach US$4 billion to US$5 billion. In addition, peak sales of 4 to 5 Phase III projects are also expected to reach more than US$1 billion, providing the company with a stable source of income. Macquarie pointed out that WuXi Biologics management aims to become the industry's first in the next three years, and reiterated its "Outperform" rating with a target price of HK$122.

Und noch einer 🙃:

Gerne! Gerade über die letzten News hatte ich mich gefreut 🍀😀

Vielen lieben Dank für die Infos, Summer.76🙏🏼!!!

WuXi Biologics (2269 HK) hits a record high market value exceeding HK$550 billion https://m.jrj.com.cn/madapter/hk/2021/06/18153032954623.shtml WuXi Biologics (2269 HK) rose over 9% to 132 Hong Kong dollars, a record high, with a market value of over 550 billion Hong Kong dollars, making it the largest pharmaceutical stock in the Hong Kong stock market by market capitalization. The stock was selected as one of the ten core potential assets of Gelonghui in 2021 "Betting on China". Analysts pointed out that WuXi Biologics CDO continues to lead, and CMO is catching up. It is expected that multiple projects will enter the commercialization stage in 2021, and the commercialization will begin in the first year.

🍀

WUXI BIO (02269 HK) Thrives 8.6% as Exec Hikes Annual Sales, Earnings Growth Forecast http://www.aastocks.com/en/stocks/news/aafn-con/rum.210618_155139/latest-news WUXI BIO's (02269 HK) senior management raised the full-year sales and earnings guidance. The bluechipper surged 8.6% to last post at $131.3, once hitting a record high at $132.

WuXi Biologics (02269 HK) was reduced by 286,500 shares held by a corporation controlled by Chairman Li Ge https://www.finet.hk/newscenter/news_content/60cc0b45bde0b3600d149a29 According to the equity information of the Hong Kong Stock Exchange, WuXi Biologics (02269 HK) was controlled by the chairman and non-executive director Li Ge on June 15 at an average price of HK$123.8492 per share. Holds 286,500 shares, involving approximately 35,482,800 Hong Kong dollars. After the reduction, Li Ge's shareholding fell to 732,821,633 shares, and the latest shareholding ratio was 17.36%.

WuXi Biologics (02269 HK) grants restricted shares https://www.finet.hk/newscenter/news_content/60cbdee6bde0b3600d1499e9 WuXi Biologics (02269 HK) announced that on June 17, 2021, it has approved the grant of a total of 13,128,486 restricted shares to 1,752 employees of the company under the plan, subject to acceptance by the grantee . GRANT OF RESTRICTED SHARES UNDER RESTRICTED SHARE AWARD SCHEME https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a210618.pdf

WuXi Biologics (02269 HK) adopts the share award plan of the Global Partner Program https://www.finet.hk/newscenter/news_content/60ca8db8bde0b3600d149949 WuXi Biologics (02269 HK) announced that on June 16, 2021, the company has adopted a global partner share award plan to further reward and motivate the group’s top employees and attract key talents to ensure the company Continued business development and growth.  ...

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2021; (2) CHANGE OF NON-EXECUTIVE DIRECTOR; AND (3) CHANGE IN COMPOSITION OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a210616.pdf

Montag müsste die Börse in HK geschlossen sein.

WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates https://www.wuxibiologics.com/News_Media-Press_Release-2021_Year-2021_06_10_WuXi_XDC_and_LegoChem_Biosciences_Signed_Memorandum_of_Understanding_for_the_Development_and_Manufacturing_of_Antibody_drug_Conjugates.html

Bank of Communications International: WuXi Biologics (02269 HK) https://www.finet.hk/newscenter/news_content/60c00dd9bde0b3600d149593 ... Die Bank wird WuXi Biologics (02269 HK/buy), das führende Unternehmen auf dem goldenen Weg des Pharma-Outsourcings, erstmals in der zweiten Hälfte des Jahres 2021 mit einem Kursziel von HK$143 auf den Markt bringen.

Bank of Communications International: Optimistic about non-cyclical value stocks in the second half of the year, the first to buy 11 shares https://m.jrj.com.cn/madapter/hk/2021/06/08170832894090.shtml

China Securities Investment: Maintain WuXi Biologics (02269) "Overweight" rating, CMO strength, competitiveness, continuous enhancement, market share expected to expand https://hk.investing.com/news/stock-market-news/article-169983